Literature DB >> 16272448

Response to acute lung infection with mucoid Pseudomonas aeruginosa in cystic fibrosis mice.

Anna M van Heeckeren1, Mark D Schluchter, Wei Xue, Pamela B Davis.   

Abstract

RATIONALE: Cystic fibrosis is caused by defects in the cystic fibrosis transmembrane conductance regulator gene, which codes for a chloride channel, but the role of this chloride channel in inflammation induced by lung infection with Pseudomonas aeruginosa remains to be defined.
OBJECTIVES: We tested the hypothesis that loss of this chloride channel alone is sufficient to cause excessive inflammation in response to inflammatory stimuli.
METHODS: We investigated the response of cystic fibrosis and wild-type mice to mucoid P. aeruginosa administered by insufflation. MEASUREMENTS: The host responses measured included survival, weight change, lung morphometry, bacterial clearance, and inflammatory mediators, and cell counts were assessed in bronchoalveolar lavage fluid. MAIN
RESULTS: Depending on the dose administered and frequency of dosing, cystic fibrosis mice experienced significantly higher mortality rates, greater weight loss, higher lung pathology scores, and higher inflammatory mediator and neutrophil levels compared with wild-type mice, even after the bacteria had been cleared. Surprisingly, bacteria were cleared just as rapidly in cystic fibrosis mice as in wild-type mice, and sepsis was not observed. Chronic lung infections could not be established with mucoid P. aeruginosa in either cystic fibrosis or wild-type mice.
CONCLUSIONS: Absence of this chloride channel alone appears sufficient for exaggerated inflammation and excess mortality compared with wild-type controls in the face of mucoid P. aeruginosa lung infection. To establish chronic infection, additional factors such as bacterial trapping or poor clearance may be required.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16272448      PMCID: PMC2662931          DOI: 10.1164/rccm.200506-917OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  26 in total

1.  Impaired ability of Cftr knockout mice to control lung infection with Pseudomonas aeruginosa.

Authors:  D Gosselin; M M Stevenson; E A Cowley; U Griesenbach; D H Eidelman; M Boulé; M F Tam; G Kent; E Skamene; L C Tsui; D Radzioch
Journal:  Am J Respir Crit Care Med       Date:  1998-04       Impact factor: 21.405

2.  Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients.

Authors:  M S Muhlebach; P W Stewart; M W Leigh; T L Noah
Journal:  Am J Respir Crit Care Med       Date:  1999-07       Impact factor: 21.405

3.  Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils.

Authors:  Travis S Walker; Kerry L Tomlin; G Scott Worthen; Katie R Poch; Jonathan G Lieber; Milene T Saavedra; Michael B Fessler; Kenneth C Malcolm; Michael L Vasil; Jerry A Nick
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

4.  Novel mouse model of chronic Pseudomonas aeruginosa lung infection mimicking cystic fibrosis.

Authors:  Nadine Hoffmann; Thomas Bovbjerg Rasmussen; Peter Østrup Jensen; Charlotte Stub; Morten Hentzer; Søren Molin; Oana Ciofu; Michael Givskov; Helle Krogh Johansen; Niels Høiby
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

5.  Alterations in the course of acid-induced lung injury in rats after general anesthesia: volatile anesthetics versus ketamine.

Authors:  N Nader-Djalal; P R Knight; M F Bacon; A R Tait; T P Kennedy; K J Johnson
Journal:  Anesth Analg       Date:  1998-01       Impact factor: 5.108

6.  Role of cystic fibrosis transmembrane conductance regulator in pulmonary clearance of Pseudomonas aeruginosa in vivo.

Authors:  Z C Chroneos; S E Wert; J L Livingston; D J Hassett; J A Whitsett
Journal:  J Immunol       Date:  2000-10-01       Impact factor: 5.422

7.  The relationship of chronic mucin secretion to airway disease in normal and CFTR-deficient mice.

Authors:  V L Cressman; E M Hicks; W K Funkhouser; D C Backlund; B H Koller
Journal:  Am J Respir Cell Mol Biol       Date:  1998-12       Impact factor: 6.914

8.  Effects of bronchopulmonary inflammation induced by pseudomonas aeruginosa on adenovirus-mediated gene transfer to airway epithelial cells in mice.

Authors:  A van Heeckeren; T Ferkol; M Tosi
Journal:  Gene Ther       Date:  1998-03       Impact factor: 5.250

9.  The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis.

Authors:  K Balough; M McCubbin; M Weinberger; W Smits; R Ahrens; R Fick
Journal:  Pediatr Pulmonol       Date:  1995-08

10.  Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa.

Authors:  A Heeckeren; R Walenga; M W Konstan; T Bonfield; P B Davis; T Ferkol
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

View more
  35 in total

1.  Lack of cystic fibrosis transmembrane conductance regulator in CD3+ lymphocytes leads to aberrant cytokine secretion and hyperinflammatory adaptive immune responses.

Authors:  Christian Mueller; Sofia A Braag; Allison Keeler; Craig Hodges; Mitchell Drumm; Terence R Flotte
Journal:  Am J Respir Cell Mol Biol       Date:  2010-08-19       Impact factor: 6.914

Review 2.  Update in cystic fibrosis 2006.

Authors:  Frank J Accurso
Journal:  Am J Respir Crit Care Med       Date:  2007-04-15       Impact factor: 21.405

3.  Parthenolide inhibits IkappaB kinase, NF-kappaB activation, and inflammatory response in cystic fibrosis cells and mice.

Authors:  Aicha Saadane; Sophia Masters; Joseph DiDonato; Jingfeng Li; Melvin Berger
Journal:  Am J Respir Cell Mol Biol       Date:  2007-02-01       Impact factor: 6.914

4.  Interleukin-17 Pathophysiology and Therapeutic Intervention in Cystic Fibrosis Lung Infection and Inflammation.

Authors:  Daniel Hsu; Patricia Taylor; Dave Fletcher; Rolf van Heeckeren; Jean Eastman; Anna van Heeckeren; Pamela Davis; James F Chmiel; Eric Pearlman; Tracey L Bonfield
Journal:  Infect Immun       Date:  2016-08-19       Impact factor: 3.441

5.  Experimental investigation of the immunoregulatory and anti-inflammatory effects of the traditional Chinese medicine "Li-Yan Zhi-Ke Granule" for relieving chronic pharyngitis in rats.

Authors:  Yiyi Sun; Zhihe Zang; Xiaohong Xu; Zhonglin Zhang; Ling Zhong; Wang Zan; Yan Zhao; Lin Sun
Journal:  Mol Biol Rep       Date:  2010-03-28       Impact factor: 2.316

6.  Quantitative microscopy in murine models of lung inflammation.

Authors:  Joseph Soltzberg; Sarah Frischmann; Christiaan van Heeckeren; Nicole Brown; Arnold Caplan; Tracey L Bonfield
Journal:  Anal Quant Cytol Histol       Date:  2011-10       Impact factor: 0.302

7.  IL-23 mediates inflammatory responses to mucoid Pseudomonas aeruginosa lung infection in mice.

Authors:  Patricia J Dubin; Jay K Kolls
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-10-27       Impact factor: 5.464

8.  Resistance to Pseudomonas aeruginosa chronic lung infection requires cystic fibrosis transmembrane conductance regulator-modulated interleukin-1 (IL-1) release and signaling through the IL-1 receptor.

Authors:  Nina Reiniger; Martin M Lee; Fadie T Coleman; Christopher Ray; David E Golan; Gerald B Pier
Journal:  Infect Immun       Date:  2007-02-05       Impact factor: 3.441

9.  Enhanced Clearance of Pseudomonas aeruginosa by Peroxisome Proliferator-Activated Receptor Gamma.

Authors:  Brahmchetna Bedi; Zhihong Yuan; Myungsoo Joo; Susu M Zughaier; Joanna B Goldberg; Jack L Arbiser; C Michael Hart; Ruxana T Sadikot
Journal:  Infect Immun       Date:  2016-06-23       Impact factor: 3.441

10.  Novel experimental Pseudomonas aeruginosa lung infection model mimicking long-term host-pathogen interactions in cystic fibrosis.

Authors:  Claus Moser; Maria Van Gennip; Thomas Bjarnsholt; Peter Østrup Jensen; Baoleri Lee; Hans Petter Hougen; Henrik Calum; Oana Ciofu; Michael Givskov; Søren Molin; Niels Høiby
Journal:  APMIS       Date:  2009-02       Impact factor: 3.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.